Transplantation To infinity and beyond July 2018 Dr Bill Monday - - PowerPoint PPT Presentation

▶
transplantation to infinity and beyond
SMART_READER_LITE
LIVE PREVIEW

Transplantation To infinity and beyond July 2018 Dr Bill Monday - - PowerPoint PPT Presentation

Dec 31, 2023 245 likes •701 views

FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL Transplantation To infinity and beyond July 2018 Dr Bill Monday Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL Overview Topics covered in this presentation

slide-1
SLIDE 1

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Transplantation – To infinity and beyond

July 2018 Dr Bill Monday

slide-2
SLIDE 2

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Topics covered in this presentation

— Overview —

01 Overview of transplantation in Australia 02 Solid organ transplantation 03Stem cell transplantation 04 Bio-printing

slide-3
SLIDE 3

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Aim of talk:

— Overview —

1.To make you all organ donors ☺ …. ( https://register.donatelife.gov.au/decide) 2.To get a feel for transplants in Australia 3.To note use of stem cell transplantation in MS 4.To ensure you don’t change your home printer into a bio-printer yet…..

slide-4
SLIDE 4

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Transplantation

slide-5
SLIDE 5

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Overview of transplantation in Australia

  • Section 01 -
slide-6
SLIDE 6

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Transplants performed in Australia from deceased donors.

6

http://www.anzdata.org.au/anzod/updates/20180606_ANZODMonthlyReport_2018May.pdf

slide-7
SLIDE 7

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Transplants performed in Australia from deceased donors.

7

http://www.anzdata.org.au/brochures/brochure_2016v1.0_20180417.pdf

slide-8
SLIDE 8

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Transplants performed in Australia from deceased donors.

8

http://www.anzdata.org.au/anzod/updates/20180606_ANZODMonthlyReport_2018May.pdf

Jan May- 2018 Number of transplants Kidney 385 Liver 127 Heart 57 Lung 184 Pancreas 18 Stomach and intestine Multi-organ Transplant Jan –May 2017 Heart and lungs 3 Kidney and Heart 4 Kidney and Liver 5 Kidney and Lungs 1 Kidney and Pancreas 16 Total 29

slide-9
SLIDE 9

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Survival of Graft 1997-2016

http://www.anzdata.org.au/brochures/brochure_2016v1.0_20180417.pdf

slide-10
SLIDE 10

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL 10

slide-11
SLIDE 11

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Solid Organ Survival Australia

1 Year 5 Year 10 Year Kidney 99-97% 96-90% 83-74 Heart 87% 81% 70% Lung 93% 70% 32%* Pancreas 96% 92% 82%

11

* USA survival data

slide-12
SLIDE 12

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Common causes of renal disease leading to renal transplant.

  • Diabetes- 31%
  • Chronic Glomerulonephritis 28%
  • Polycystic Kidney Disease-12%
  • Nephrosclerosis 9%
  • Lupus 3%
  • Interstitial Nephritis 3%
  • Other 14%

12

slide-13
SLIDE 13

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Outcomes after transplants

Standardised mortality per 100 patient years:

  • Dialysis 6.3
  • Cadaveric transplant 3.8
  • Living Donor transplant 2.0
slide-14
SLIDE 14

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Causes of death in renal transplant patients

14

tp://www.anzdata.org.au/anzdata/AnzdataReport/40thReport/chapter03_mortality_2016_v1.0_20180411.pdfht

slide-15
SLIDE 15

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Long term complications of transplantation

  • Cardiovascular disease (Death With a Functioning Graft- DWFG) 7.6% chance of MI or

coronary revascularization after 5 years.

  • Why?
  • More calcification in arteries
  • More LVH.
  • Caution esp in-
  • Diabetics,
  • CVS disease during dialysis
  • Ongoing proteinuria.
  • Renal function post transplant also NB with a 16% increase in CVS events for every

5ml/min/1.73m2 decrease below a eGFR of 45ml/min/1.73m2

  • Immunosuppression including steroids increase BP and increase dyslipidaemia.

15

https://academic.oup.com/bmb/article/106/1/117/322190. Update on long term complications of renal transplantation Mathew J Bottomley et at British Medical Bulletin 02 May 2013

slide-16
SLIDE 16

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Long term complications of transplantation

  • Cancer (DWFG)
  • Cardiovascular disease and cancer account for 47% of all deaths with a functioning

graft with 27% of death being due to cancer)

  • Majority of cancers are Non Melanoma Skin Cancers (NMSC)
  • Lymphomas higher than the general population
  • Kaposi’s Sarcoma more common in transplanted patients

16

https://academic.oup.com/bmb/article/106/1/117/322190. Update on long term complications of renal transplantation Mathew J Bottomley et at British Medical Bulletin 02 May 2013

slide-17
SLIDE 17

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Long term complications of transplantation- Cancer

17

https://academic.oup.com/bmb/article/106/1/117/322190. Update on long term complications of renal transplantation Mathew J Bottomley et at British Medical Bulletin 02 May 2013

slide-18
SLIDE 18

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Immunosuppresssion

  • All kidney transplants require life long immunosuppression to prevent T cell rejection. It’s

a bit of a balance as you need to:

  • Prevent acute and chronic rejection.
  • Minimize drug toxicity and rates of infection and malignancy

Complications include:

  • Rejection
  • Nephrotoxicity of certain immunosuppressive drugs such as Cyclosporin and Tacrolimus
  • Recurrence of native kidney disease
  • Acute rejection occurs in first 6 months (15% of cases)
  • Chronic rejection occurs more than a year after transplantation

18

slide-19
SLIDE 19

Pacific Life Re FOR INTERNAL USE ONLY / PRIVATE & CONFIDENTIAL

Complications of common Transplant drugs

Complications CVS Carcinogenesis Other Nephrotoxicity Ciclosporin ↑BP, ↑ Lipids, ↑ Diabetes risk Yes, carcinogenic Pancreatitis, All transplants have impaired function ( even if biochemically normal) . To avoid any medication that may effect the kidney such as NSAIDs, Certain antibiotics such as Aminoglycosides Tacrolimus ↑BP, ↑ Lipids, ↑ Diabetes risk No carcinogenesis Insomnia Headaches Azathioprine No effect Yes, carcinogenic Low White cell count Mycophenolate ↑ Lipids Possible, some evidence Teratogenic Sirolimus ↑ Lipids Possible, some evidence Pneumonititis,

  • edema

Everolimus ↑ Lipids Possible, some evidence Pneumonititis,

  • edema

Corticosteroids ↑BP, ↑ Lipids, ↑ Diabetes risk Limited evidence

19

slide-20
SLIDE 20

Pacific Life Re FOR INTERNAL USE ONLY / PRIVATE & CONFIDENTIAL

Underwriting considerations of transplanted patient- Kidney.

Deceased or living donor in case of kidney Present renal function- preferably eGFR, Creat below 150 as rule of thumb Presence of proteinuria , hypertension Cardiovascular, cancer and diabetic risk Medication and side–effects of medication.

20

https://academic.oup.com/bmb/article/106/1/117/322190. Update on long term complications of renal transplantation Mathew J Bottomley et at British Medical Bulletin 02 May 2013

slide-21
SLIDE 21

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL 21

slide-22
SLIDE 22

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Stem Cell Transplantation.

  • Section 03 -
slide-23
SLIDE 23

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Stem cell transplants – Around a 1000/year in Australia

23

Indications:

  • Leukaemia
  • Lymphoma
  • Myeloma
  • Amyloidosis
  • Aplastic anaemia
  • Some solid tumours (e.g testicular cancer, breast cancer)
  • Some immune system disorders (scleroderma)
  • MS
slide-24
SLIDE 24

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Stem Cell Transplant.

24

A stem cell transplant replaces blood forming cells in your bone marrow that have been destroyed by chemotherapy or radiotherapy with healthy stem cells A stem cell transplant can be your own stem cells ( Autologous 2/3 of cases ) or stem cells from a donor ( Allogenic) Stem cell transplants have 4 main phases 1)Stem cell collection from you or a donor (1-2 weeks) 2)Transplant treatment (Chemotherapy or radiotherapy – 1 week) 3) IV transfusion of healthy Stem cells (1 day) 4) Recovery 2-12 weeks

slide-25
SLIDE 25

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Survival after Stem cell transplant

Survival improving due to better tissue matching, better supportive care and earlier referral for transplantation. Allogenic bone marrow transplants potentially curative with most deaths occurring in the first 2 years post transplant. 5 Year survival 89% and 10 year survival 85%. Causes of death-

– Age related – Relapse of malignancy – Chronic Graft Versus Host Disease ( GVHD) – Second cancers ( 2-10% of deaths in late survivors)

Australia at the forefront creating blood stem cells in the lab. Used pluripotent stem cells to create blood cells

25

slide-26
SLIDE 26

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Graft Vs Host Disease

This can only occur in Allogenic transplants The donated bone marrow/stem cells see the recipient’s body as foreign and attack, Graft vs Host disease can be acute or chronic GVHD can affect the skin, liver, eyes, mouth, lungs, GIT tract, neuromuscular system or genitourinary system. Immunosuppressives are prescribed thus increasing infection risk.

26

slide-27
SLIDE 27

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Fairly predictable and favourable prognosis after 2 years

  • f survival

27

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107742/

slide-28
SLIDE 28

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Stem cell Transplantation in MS

  • Section 02 -
slide-29
SLIDE 29

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

MS- Different subtypes.

Relapsing Remitting ( RRMS-85%) Secondary Progressive MS ( SPMS- Rare) Primary Progressive MS ( PPMS- 10%) Progressive relapsing MS ( PRMS-5%)

29

https://www.multiplesclerosis.com/us/treatment.php

slide-30
SLIDE 30

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Types of MS

30

Relapsing Remitting MS Secondary progressive MS Progressive relapsing MS Primary Progressive MS Time Time Time Time Increasing symptoms and/or disability Increasing symptoms and/or disability Increasing symptoms and/or disability Increasing symptoms and/or disability

slide-31
SLIDE 31

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

MS- Treatment

Methylprednisolone (Solu-medrol) Dexamethasone Beta interferons Glatiramer acetate Fingolimod Teriflunomide Dimethyl fumarate Mitoxantrone Natalizumab

31

https://www.multiplesclerosis.com/us/treatment.php

slide-32
SLIDE 32

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

MS- Cell based therapy

32

slide-33
SLIDE 33

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Stem cell transplantation for MS.

33

1. I/AHSCT. Intensive chemo to kill immune system- Immuno-Ablative Haematopoietic Stem Cell Transplant. Cost $80,000 2. Mesenchymal Stem Cells +/- 2 million stem cells reintroduced with more normal immune function. Rebooting the immune system without it attacking the body uses a different kind of stem cell which is isolated from different tissue including bone marrow and fat. Mesenchymal stem cells secrete chemicals that dampens the immune system and a milieu that is more supportive for self repair of the central nervous system. 3. Use of oligodendrocyte progenitor cells

slide-34
SLIDE 34

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bio-printing

  • Section 04 -
slide-35
SLIDE 35

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bioprinting

Bio-printing

35

slide-36
SLIDE 36

Pacific Life Re FOR INTERNAL USE ONLY / PRIVATE & CONFIDENTIAL

Bio-printing

  • Testing of Cosmetics and other consumer goods
  • Drug screening
  • Personalised medicine
  • Regenerative Medicine (Bone and cartilage, skin, dental, vasculature, complex
  • rgans)
  • Cell-based Biosensors
  • Food and other animal products
  • Education
  • Academic research
  • Bionics
  • Market expected to reach a value of $1.9 Billion by 2028.
slide-37
SLIDE 37

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bio-printing

slide-38
SLIDE 38

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bio-printing- Biomimicry

Biomimicry involves the identical reproduction of the cellular and extracellular components of a tissue

  • r organ. An example would be the

mimicking of the branching patterns

  • f blood vessels.
slide-39
SLIDE 39

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bio-printing- Autonomous self assembly

This uses embryonic organ development as a guide. The early cells produce their own extra cellular matrix, appropriate cell signalling and autonomous organization to produce the right micro-architecture and functioning.

slide-40
SLIDE 40

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Bioprinting- Mini- Tissues.

Organs and tissues comprise of smaller, functional building blocks- mini tissues. Mini tissues can be fabricated and assembled by rational design or self assembly or a combination of both

slide-41
SLIDE 41

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

  • 1. Imaging- X-ray, CT, MRI
  • 2. Design approach-Biomimicry, self- assembly. Mini-tissues
  • 3. Material selection
  • 4. Cell selction –differentiated cells, multipotent stem cells
  • 5. Bio-printing-Inkjet. Micro-extrusion, laser assisted
  • 6. Application- Maturation, implantation, in vitro testing

Bio-printing- Multi-Stepped Approach

slide-42
SLIDE 42

Pacific Life Re FOR INTERNAL USE ONLY / PRIVATE & CONFIDENTIAL

Bioprinting- Considerations

Rejection remains a problem unless autologous cells used Many primary cells are difficult to isolate and culture and have a finite life span. Embryonic stem cells and pluripotent stem cells hold great promise due to indefinite self renewal. Still need increased resolution, speed and compatibility with biologically relevant materials. Cross linking of cells and the extracellular matrix are ongoing challenges Building a vascular tree and perfusion remains challenging. It is thought a Human D organ is around 1o -15 years away

slide-43
SLIDE 43

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL

Reinvent Thank You

slide-44
SLIDE 44

Pacific Life Re FOR INTERNAL USE ONLY | PRIVATE & CONFIDENTIAL 44

For more information, please contact: Name Dr Bill Monday Pacific Life Re | CMO T: +610282748634 E: bill.monday@pacificlifere.com W: www.pacificlifere.com

Contact Contact

The views contained in this document are confidential, do not constitute advice and are not intended to be relied upon as such. While this information has been prepared in good faith, no representation or warranty, express or implied, is or will be made and no responsibility or liability is or will be accepted in relation to the accuracy or completeness of the information contained herein and any such liability is expressly disclaimed.